| abstract |
A use of one or more compounds of formula (I) or a pharmaceutical acceptable salt or solvate thereof, in combination with other classes of pharmaceutical compounds; for the manufacture of one or more medicaments for treating a CXC chemokine mediated disease is disclosed, wherein the variables shown in formula (I) are as defined in the specification. These compounds of formula (I) in combination with other classes of pharmaceutical compounds are particularly suitable for treating chemokine-mediated diseases such as acute and chronic inflammatory disorders, psoriasis, cystic fibrosis, asthma, cancer and many other diseases as disclosed in the specification. |